Last reviewed · How we verify
Benaglutide Injection
Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.
Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Benaglutide Injection |
|---|---|
| Also known as | Benaglutide Injection, rhGLP-1(7-36) |
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Benaglutide mimics glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells. This mechanism helps lower blood glucose levels in patients with type 2 diabetes. The drug also slows gastric emptying and promotes satiety, contributing to improved glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
Key clinical trials
- Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity (NA)
- Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults (PHASE1)
- Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients (PHASE3)
- Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benaglutide Injection CI brief — competitive landscape report
- Benaglutide Injection updates RSS · CI watch RSS
- The Affiliated Hospital of Qingdao University portfolio CI